OKYO
OKYO Pharma Limited
1W: +0.6%
1M: -9.0%
3M: -15.7%
YTD: -27.8%
1Y: +19.3%
3Y: +16.7%
$1.68
+0.02 (+1.20%)
After Hours: $1.63 (-0.05, -2.98%)
Weekly Expected Move ±5.9%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$64.5M
52W Range1.03-3.349
Volume71,496
Avg Volume269,772
Beta-0.15
Dividend—
Analyst Ratings
Company Info
CEORobert J. Dempsey
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2022-05-17
Websiteokyopharma.com
55 Park Lane
London W1K 1NA
GB
London W1K 1NA
GB
44 20 7495 2379
About OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest News
Most and least shorted healthcare stocks with up to $2B market cap in March
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CERRONE GABRIELE M | J-Other | 70,071 | $1.50 | 2023-10-27 |
| CERRONE GABRIELE M | J-Other | 499,468 | $1.50 | 2023-10-23 |
| BRANCACCIO JOHN P | P-Purchase | 16,670 | $1.50 | 2023-09-15 |
| CERRONE GABRIELE M | P-Purchase | 5,800,000 | $0.08 | 2022-05-19 |
| JACOB GARY S | P-Purchase | 12,500 | $4.00 | 2022-05-19 |